Cerulean Pharma Inc (NASDAQ:CERU), a leading clinical stage company actively involved in the nanoparticle-drug conjugate development, announced the publication of its lead compound, CRLX101’s clinical data. As per the reports, the data has been published in the journal of National Academy of Sciences.
Insights of Matter
The data announced through this way comprises of results achieved in an investigator-sponsored trial. The research took into consideration pre-treatment and post-treatment tumor biopsies of those patients who are suffering from gastric cancer and treated with Cerulean’s lead compound CRLX101. Scientists inhibited the molecular targets of CRLX101 in post-treatment biopsies.
Reports claim that the article was first published online to know the feedback of experts and cover a broad range of audience from day one. The initial results of this trial were discussed at one of the most sought after events in this field – 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
According to Dr. Mark Davis, Ph.D., and his colleagues, CRLX101 is good enough to deliver a result-oriented anti-cancer drug to patients’ tumors without damaging healthy tissues. Earlier, many researchers tried to achieve this status, but they failed to create an NDC that could incorporate camptothec.
As soon as the data was published, many field experts came ahead in the support of CRLX101 saying that this clinical trial is an accurate demonstration of how powerful can NCDs be in real life. According to Christopher D.T. Guiffre, CEO & President, Cerulean, gone are those days when dynamic tumor targeting was shown only in rodents. With CRLX101, it can now be used in humans as well. Previously, it was tough to target tumors and spare healthy tissues in oncology; however, it has become possible now.
Going forward, Cerulean will continue to make further improvements in CRLX101 to make it fully optimized for positive results in cancer patients all around the globe.